Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

Adam Feuerstein @JNapodano Isn’t this $AMBS

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30069
Posted On: 12/06/2014 6:22:18 PM
Avatar
Posted By: cannoli1
Quote:
Adam Feuerstein
@JNapodano Isn’t this $AMBS deal a bit too much mission creep?
1:24pm - 17 Nov 14

Jason Napodano
@adamfeuerstein Not sure what you mean. Like taking on more than they can handle? Maybe GC can get advice from Martin? LOL
1:27pm - 17 Nov 14

Adam Feuerstein
@JNapodano Yes. How does skin substitutes fit into $AMBS?
1:27pm - 17 Nov 14

Jason Napodano
@adamfeuerstein Off the cusp, I think GC's strategy is to roll-up Orphan drugs, regardless of area of focus or indication. But fair point.
1:29pm - 17 Nov 14



I think the BOD would agree about becoming too "diffused" following the ESS acquisition if their plan was to actually hold onto lympro.

Quote:
Dr. Rubinfeld: Well the greatest challenge was actually not to overgrow and to become too diffused in what we are doing. In other words, I want to concentrate on the product line that we have now and the products in the pipeline to bring them to fruition. And toward that end, we also have strategies of spinouts and things of that sort. If we cannot really give the full advantage to some of these products to reach full potential, maybe then we would out- license them or spin them out into another company or division that could concentrate on them. We have this huge pipeline. We have a lot of products out there. We have probably the most patients in clinical trials in oncology in the United States so this is an enormous challenge. http://www.twst.com/interview/827







(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us